Journal Information
Most often read
3814
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, ... NAFLD Nomenclature consensus group
Ann Hepatol. 2024;29:101133
3814
Full text access
3693
Evolving portal hypertension through Baveno VII recommendationsManuel Mendizabal, Guilherme Grossi Lopes Cançado, Agustín Albillos
Ann Hepatol. 2024;29:101180
3693
Full text access
3032
Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cellsShuguang Pan, Ying Hu, Lang Gan, Jiejuan Lai, Ping Zheng, YuJun Zhang, Ling Shuai, Yan Jiang, ... Yu He
Ann Hepatol. 2024;29:101279
3032
Full text access
2784
Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysisShudi Li, Fei Duan, Suling Li, Baoping Lu
Ann Hepatol. 2024;29:101174
2784
Full text access
2378
Alcohol-associated liver disease: Epidemiology and managementHelena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller
Ann Hepatol. 2024;29:101162
2378
Full text access
2071
From NAFLD to MASLD: When metabolic comorbidity mattersShan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
Ann Hepatol. 2024;29:101281
2071
Full text access
1702
The burden of liver disease in Latin AmericaLuis Antonio Díaz, Marcela Villota-Rivas, Francisco Barrera, Jeffrey V. Lazarus, Marco Arrese
Ann Hepatol. 2024;29:101175
1702
Full text access
1457
Why a pinch of zinc in liver disease mattersKurt Grüngreiff, Dirk Reinhold, Wolfgang Maret
Ann Hepatol. 2024;29:101152
1457
Full text access
1335
Schistosomiasis: A neglected cause of liver disease in the PhilippinesAlexander M. Sy
Ann Hepatol. 2024;29:101166
1335
Full text access
1198
From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner
Ann Hepatol. 2024;29:101185
1198
Full text access
873
A data-driven approach to decode metabolic dysfunction-associated steatotic liver diseaseMaria Jimenez Ramos, Timothy J. Kendall, Ignat Drozdov, Jonathan A. Fallowfield
Ann Hepatol. 2024;29:101278
873
Full text access
866
Prevalence of occult hepatitis B virus infection and characterisation of hepatitis B surface antigen mutants among adults in western CroatiaMarina Bubonja-Šonje, Dolores Peruč, Maja Abram, Bojana Mohar-Vitezić
Ann Hepatol. 2024;29:101156
866
Full text access
836
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Michael Crutchlow, Gail Fernandes, Samuel S Engel, Xiao Zhang
Ann Hepatol. 2024;29:101154
836
Full text access
826
Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma careInah Marie C. Aquino, Devis Pascut
Ann Hepatol. 2024;29:101176
826
Full text access
783
NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective studyRenling Yao, Sufang Lu, Ruifei Xue, Jian Wang, Yuanwang Qiu, Yuxin Chen, Jiacheng Liu, Li Zhu, ... Chao Wu
Ann Hepatol. 2024;29:101155
783
Full text access
745
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFTJeremy Lee, Christopher J. Byrne, Paul N. Brennan, Iain MacPherson, Eleanor Dow, John F. Dillon
Ann Hepatol. 2024;29:101280
745
Full text access
742
The landscape of inpatient admissions for alcoholic hepatitis in the era of early liver transplantationShahana Prakash, Tomohiro Tanaka
Ann Hepatol. 2024;29:101169
742
Full text access
735
Global prevalence of occult HBV infection in children and adolescents: A systematic review and meta-analysisJiaying Wu, Jiayao He, Hongmei Xu
Ann Hepatol. 2024;29:101158
735
Full text access
713
Ending stigmatizing language in alcohol and liver disease: A liver societies' statementAnn Hepatol. 2024;29:101143
713
Full text access
706
Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani
Ann Hepatol. 2024;29:101153
706
Full text access